查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球癌症分析市場評估：按生物標記類型、按技術、按癌症類型、按應用、按最終用戶、按地區、機會、預測（2017-2031）
市場調查報告書
商品編碼
1400696

全球癌症分析市場評估：按生物標記類型、按技術、按癌症類型、按應用、按最終用戶、按地區、機會、預測（2017-2031）

Global Cancer Profiling Market Assessment, By Biomarker Type, By Technology, By Cancer Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 217 Pages | 商品交期: 3-5個工作天內

價格

全球癌症分析市場規模預計到 2023 年將達到 111.6 億美元，到 2031 年將達到 225.3 億美元，2024-2031 年預測期間複合年增長率為 9.18%。市場非常活躍，培育了許多市場公司。隨著全球癌症患者數量的增加，預計該市場將大幅成長。

據世界衛生組織稱，癌症是全球第二大死因。癌症盛行率的快速增加可歸因於基因突變、酒精和菸草的消費、荷爾蒙和生活方式的改變以及致癌微生物感染，這些都是推動全球癌症分析市場的關鍵因素。針對這一事實，醫療保健專業人士和市場參與者正在專注於開發更先進的解決方案，例如用於準確癌症診斷的癌症分析，以減輕癌症負擔。

腫瘤分析使醫療保健專業人員能夠根據個人獨特的基因圖譜開發個人化治療，從而獲得高效的治療結果。由於人工智慧和機器學習等技術用於癌症診斷和預測，癌症分析市場正在擴大。

癌症盛行率增加

癌症是已開發國家和發展中國家的主要原因之一。輻射暴露、飲酒和吸煙以及生活方式的改變是全球癌症患者數量不斷增加的主要原因。由於可用於癌症分析和治療的精確診斷的發展，預計癌症分析市場的成長。在這種情況下，癌症分析對於提供客製化和替代治療至關重要，這進一步推動了全球癌症分析市場的成長。根據世界衛生組織預測，2025年，新診斷癌症病例數預計將增加約2,162萬例，成長率為12.1%。在所有病例中，乳癌是世界上最常見的癌症。乳癌居所有癌症之首，佔12%。

對個人化治療的偏好日益增加

透過個人化治療可以改善癌症治療的治療結果。腫瘤和癌症分析是個人化治療開發的第一步，正在推動市場創新和成長。在基因組技術進步的指導下，這種個人化方法提高了治療效果，減少了副作用，並改善了患者的治療結果。癌症分析在臨床試驗設計中的整合、免疫療法的日益普及以及政府的支持性舉措都有助於在癌症治療中越來越多地採用個人化醫療。

政府的努力

世界各國政府正在透過宣傳活動積極促進癌症篩檢和治療，這推動了全球癌症分析市場的成長。政府資助針對癌症診斷技術的研究計畫。2023年3月，美國政府將向三個CDC項目投資3.945億美元：National Comprehensive Cancer Control Program、National Breast and Cervical Cancer Early Detection Programs、Colorectal Cancer Control Program，以減輕國家的癌症負擔。2023年1月，政府宣布將投資1,000萬歐元新建29個乳癌篩檢設施，以降低英國乳癌的發生率。

COVID-19 的影響

COVID-19 大流行對全球癌症分析市場產生了重大影響。癌症患者是最脆弱的人之一。癌症篩檢對於癌症控制和預防至關重要，但由於 COVID-19 大流行，許多篩檢被取消或推遲，影響了許多患者獲得所需護理的機會。COVID-19 導致癌症分析市場中斷，對患者、醫療保健專業人員和醫療保健系統產生了巨大影響。根據 2022 年 6 月發表在 SAGE 上的一篇論文，從 2019 年到 2020 年，用於乳癌篩檢的乳房 X 光檢查減少了 44%。

本報告研究和分析了全球癌症分析市場，提供市場規模和預測、市場動態以及主要參與者的現狀和前景。

目錄

第一章研究方法論

第二章 專案範圍與定義

第 3 章 COVID-19 對全球癌症分析市場的影響

第 4 章執行摘要

第五章 全球癌症分析市場展望（2017-2031）

  • 市場規模及預測
    • 金錢數額
    • 數量
  • 依生物標誌類型
    • 基因生物標記
    • 蛋白質生物標記
    • 其他癌症生物標記
  • 按技術
    • 免疫學檢查
    • 下一代測序 (NGS)
    • 聚合□鍊式反應 (PCR)
    • 原位雜交 (ISH)
    • 微陣列
    • 光譜學
    • 其他
  • 按癌症類型
    • 乳腺癌
    • 肺癌
    • 大腸癌
    • 黑色素瘤
    • 血癌
    • 前列腺癌
    • 卵巢癌
    • 胃癌
    • 肝癌
    • 其他癌症
  • 按用途
    • 臨床應用
    • 研究用途
  • 按最終用戶
    • 院內診斷實驗室
    • 診斷中心
    • 癌症研究所
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 市場佔有率：依公司劃分（2022 年）

第七章 全球癌症分析市場展望（2017-2031）

  • 北美
    • 市場規模及預測
    • 依生物標誌類型
    • 按技術
    • 按癌症類型
    • 按用途
    • 按最終用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 意大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印度尼西亞
    • 菲律賓
  • 中東/非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 南非

第 8 章 市場測繪（2023 年）

  • 依生物標誌類型
  • 按技術
  • 按癌症類型
  • 按用途
  • 按最終用戶
  • 按地區

第九章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析 - 數量和價值
  • 供應/價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第十章市場動態

  • 增長動力
  • 成長限制因素（問題、限制因素）

第十一章 監理框架與創新

  • 臨床試驗
  • 專利情況
  • 監管審批
  • 創新/新技術

第十二章 主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析（2023 年）
  • 併購/合資（如適用）
  • SWOT分析（針對5家進入市場的公司）
  • 專利分析（如果適用）

第13章價格分析

第14章案例研究

第十五章 主要公司展望

  • Illumina, Inc.
  • QIAGEN NV
  • NeoGenomics Laboratories, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Genomic Health Inc.
  • Caris Life Sciences
  • Helomics Corporation
  • NanoString Technologies, Inc.
  • Sysmex Corporation
  • Ribomed Biotechnologies, Inc.
  • Guardant Health, Inc.
  • Foundation Medicine
  • Roche Holding AG
  • GenScript Biotech Corporation
  • Tempus Labs, Inc.

第十六章 策略建議

第十七章 關於我們公司、免責聲明

Product Code: MX10781

Global cancer profiling market size was valued at USD 11.16 billion in 2023, expected to reach USD 22.53 billion in 2031, with a CAGR of 9.18% for the forecast period between 2024 and 2031F. The global cancer profiling market is highly dynamic, fostering many market players. The market is expected to grow exponentially due to the increasing number of cancer cases around the world.

As per WHO, cancer is the second leading cause of death globally. The surge in the prevalence of cancer can be attributed to inherited mutations, alcohol and tobacco consumption, hormonal and lifestyle changes, and carcinogenic microbial infections, which play an important role in driving the global cancer profiling market. Owing to this fact, healthcare professionals and market players are focused on developing more advanced solutions like cancer profiling for precise cancer diagnosis to reduce the cancer burden.

Tumor profiling enables healthcare professionals to develop personalized therapy based on unique genetic profiles of individuals, leading to highly effective therapeutic outcomes. The market for cancer profiling is expanding due to the use of technology such as artificial intelligence and machine learning for cancer diagnosis and prediction.

Growing industry partnerships, the introduction of cutting-edge products, and government programs to promote cancer screening are expected to fuel market expansion throughout the projected period. In July 2023, the pioneer in diagnostic information services, Quest Diagnostics, announced the introduction of a new prostate cancer biomarker test via its subspecialty pathology company, AmeriPath, in association with Envision Sciences. The goal of the new tissue-based test service is to assist in meeting the urgent clinical demand for diagnostics that can distinguish between aggressive and less aggressive cases of prostate cancer in men.

Increasing Prevalence of Cancer

Cancer is one of the leading causes of death in developed and developing countries. Exposure to radiation, alcohol and tobacco consumption, and lifestyle changes are the major contributors to the increasing number of cancer patients globally. The market for cancer profiling is expected to grow due to the development of precise diagnostics that can be used to profile and treat cancer. In this case, cancer profiling becomes essential for offering customized treatment alternatives, which further propels the growth of global cancer profiling market. As per WHO, newly diagnosed cancer cases are expected to increase to around 21.62 million with a growth rate of 12.1% by 2025. Among all cases, breast cancer is the world's most prevalent cancer. Breast cancer ranks first among all types of cancer accounting for 12% share.

Growing Preference to Personalized Therapies

Improved outcomes in cancer treatments can be achieved by personalized therapy. Tumor or cancer profiling is the preliminary step in the development of personalized therapy, which drives innovation and growth in the market. This personalized approach, guided by advancements in genomic technologies, increases treatment efficacy, reduces adverse effects, and improves patient outcomes. The integration of cancer profiling in clinical trial design, increasing popularity of immunotherapy, and supportive government initiatives contribute to the growing adoption of personalized medicine in cancer care.

In March 2023, Artera invested USD 90 million to customize treatment for prostate cancer. The business will use the money to distribute its ArteraAI Prostate Test and create tests that would enable customized treatment plans for various cancers. By examining the patient's clinical information and biopsy images, Artera's multimodal AI-powered test for prostate cancer patients, known as the ArteraAI Prostate Test, assists in forecasting the possible advantages of treatment and the patient's prognosis.

Government Initiatives

Governments around the globe are actively pushing cancer screening and therapies through awareness campaigns, which is driving growth in the worldwide cancer profiling market. The government is funding research projects targeting cancer diagnosis techniques. In March 2023, the United States government invested USD 394.5 million in three CDC programs, National Comprehensive Cancer Control Program, National Breast and Cervical Cancer Early Detection Programs, and the Colorectal Cancer Control Program to reduce the cancer burden of the country. In January 2023, to decrease the incidence of breast cancer in the United Kingdom, government announced investment of EUR 10 million to build 29 new breast cancer screening facilities.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the global cancer profiling market. Cancer patients were amongst the most vulnerable populations. Although cancer screening is essential for controlling and prevention of cancer, a large number of screenings were canceled or postponed as a result of the COVID-19 pandemic, affecting a large number of patients for access to necessary medical care. There was large scale impact on patients, medical professionals, and health system from the disruption caused by COVID-19 on cancer profiling market. According to a paper published in SAGE in June 2022, between 2019 and 2020, there was a 44% decrease in breast cancer screening mammography.

Key Players Landscape and Outlook

Market players are employing a range of strategies to increase their range of solutions offered while giving their customers access to a wide selection of innovative and cutting-edge products. Additionally, companies are expanding the range of diagnostic services they offer to capture a large portion of the market. Many major industry players are using both organic and inorganic growth techniques, like partnerships, mergers and acquisitions, and launch of new products, to strengthen their position in the global market.

In April 2023, Agilent Technologies introduced a CGP test intended for somatic variant profiling. The technique, known as Agilent SureSelect Cancer CGP, decreases hands-on time and increases workflow efficiency to enable scientists to profile a larger variety of tumor samples. The pan-cancer test was developed based on a next-generation sequencing (NGS) panel of 679 genes compiled from cancer databases and research collaborations.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Cancer Profiling Market

4. Executive Summary

5. Global Cancer Profiling Market Outlook, 2017-2031F

  • 5.1 Market Size & Forecast
    • 5.1.1 By Value
    • 5.1.2 By Volume
  • 5.2 By Biomarker Type
    • 5.2.1 Genetic Biomarkers
    • 5.2.2 Protein Biomarkers
    • 5.2.3 Other Cancer Biomarkers
  • 5.3 By Technology
    • 5.3.1 Immunoassays
    • 5.3.2 Next-generation Sequencing (NGS)
    • 5.3.3 Polymerase Chain Reaction (PCR)
    • 5.3.4 In Situ Hybridization (ISH)
    • 5.3.5 Microarrays
    • 5.3.6 Spectroscopic Method
    • 5.3.7 Others
  • 5.4 By Cancer Type
    • 5.4.1 Breast Cancer
    • 5.4.2 Lung Cancer
    • 5.4.3 Colorectal Cancer
    • 5.4.4 Melanoma
    • 5.4.5 Blood Cancer
    • 5.4.6 Prostate Cancer
    • 5.4.7 Ovarian Cancer
    • 5.4.8 Stomach Cancer
    • 5.4.9 Liver Cancer
    • 5.4.10 Other Cancer
  • 5.5 By Application
    • 5.5.1 Clinical Application
      • 5.5.1.1 Diagnostics
      • 5.5.1.2 Prognostics
      • 5.5.1.3 Monitoring and Treatment
      • 5.5.1.4 Screening
    • 5.5.2 Research Application
      • 5.5.2.1 Biomarker Discovery
      • 5.5.2.2 Drug Development
  • 5.6 By End-user
    • 5.6.1 Hospital Associated Diagnostic Laboratories
    • 5.6.2 Diagnostic Centers
    • 5.6.3 Cancer Research Institutes
    • 5.6.4 Others
  • 5.7 By Region
    • 5.7.1 North America
    • 5.7.2 Europe
    • 5.7.3 Asia-Pacific
    • 5.7.4 South America
    • 5.7.5 Middle East & Africa
  • 5.8 By Company Market Share (%), 2022

7. Global Cancer Profiling Market Outlook, 2017-2031F

  • 7.1. North America
    • 7.1.1. Market Size & Forecast
      • 7.1.1.1. By Value
      • 7.1.1.2. By Volume
    • 7.1.2. By Biomarker Type
      • 7.1.2.1. Genetic Biomarkers
      • 7.1.2.2. Protein Biomarkers
      • 7.1.2.3. Other Cancer Biomarkers
    • 7.1.3. By Technology
      • 7.1.2.1 Immunoassays
      • 7.1.2.2 Next-generation Sequencing (NGS)
      • 7.1.2.3 Polymerase Chain Reaction (PCR)
      • 7.1.2.4 In Situ Hybridization (ISH)
      • 7.1.2.5 Microarrays
      • 7.1.2.6 Spectroscopic Method
      • 7.1.2.7 Others
    • 7.1.3 By Cancer Type
      • 7.1.3.1 Breast Cancer
      • 7.1.3.2 Lung Cancer
      • 7.1.3.3 Colorectal Cancer
      • 7.1.3.4 Melanoma
      • 7.1.3.5 Blood Cancer
      • 7.1.3.6 Prostate Cancer
      • 7.1.3.7 Ovarian Cancer
      • 7.1.3.8 Stomach Cancer
      • 7.1.3.9 Liver Cancer
      • 7.1.3.10 Other Cancer
    • 7.1.4 By Application
      • 7.1.4.1 Clinical Application
      • 7.1.4.1.1 Diagnostics
      • 7.1.4.1.2 Prognostics
      • 7.1.4.1.3 Monitoring and Treatment
      • 7.1.4.1.4 Screening
      • 7.1.4.2 Research Application
      • 7.1.4.2.1 Biomarker Discovery
      • 7.1.4.2.2 Drug Development
    • 7.1.4. By End-user
      • 7.1.4.1. Hospital Associated Diagnostic Laboratories
      • 7.1.4.2. Diagnostic Centers
      • 7.1.4.3. Cancer Research Institutes
      • 7.1.4.4. Others
    • 7.1.5. United States*
      • 7.1.5.1. Market Size & Forecast
      • 7.1.5.1.1. By Value
      • 7.1.5.1.2. By Volume
      • 7.1.4.1 By Biomarker Type
      • 7.1.5.1.3. Genetic Biomarkers
      • 7.1.5.1.4. Protein Biomarkers
      • 7.1.5.1.5. Other Cancer Biomarkers
      • 7.1.5.2. By Technology
      • 7.1.4.2.1 Immunoassays
      • 7.1.4.2.2 Next-generation Sequencing (NGS)
      • 7.1.4.2.3 Polymerase Chain Reaction (PCR)
      • 7.1.4.2.4 In Situ Hybridization (ISH)
      • 7.1.4.2.5 Microarrays
      • 7.1.4.2.6 Spectroscopic Method
      • 7.1.4.2.7 Others
      • 7.1.4.3 By Cancer Type
      • 7.1.4.3.1 Breast Cancer
      • 7.1.4.3.2 Lung Cancer
      • 7.1.4.3.3 Colorectal Cancer
      • 7.1.4.3.4 Melanoma
      • 7.1.4.3.5 Blood Cancer
      • 7.1.4.3.6 Prostate Cancer
      • 7.1.4.3.7 Ovarian Cancer
      • 7.1.4.3.8 Stomach Cancer
      • 7.1.4.3.9 Liver Cancer
      • 7.1.4.3.10 Other Cancer
      • 7.1.4.4 By Application
      • 7.1.4.4.1 Clinical Application
      • 7.1.4.4.1.1 Diagnostics
      • 7.1.4.4.1.2 Prognostics
      • 7.1.4.4.1.3 Monitoring and Treatment
      • 7.1.4.4.1.4 Screening
      • 7.1.4.4.2 Research Application
      • 7.1.4.4.2.1 Biomarker Discovery
      • 7.1.4.4.2.2 Drug Development
      • 7.1.4.5 By End-user
      • 7.1.4.5.1 Hospital Associated Diagnostic Laboratories
      • 7.1.4.5.2 Diagnostic Centers
      • 7.1.4.5.3 Cancer Research Institutes
      • 7.1.4.5.4 Others
    • 7.1.5 Canada
    • 7.1.6 Mexico

All segments will be provided for all regions and countries covered

  • 7.2 Europe
    • 7.2.2 Germany
    • 7.2.3 France
    • 7.2.4 Italy
    • 7.2.5 United Kingdom
    • 7.2.6 Russia
    • 7.2.7 Netherlands
    • 7.2.8 Spain
    • 7.2.9 Turkey
    • 7.2.10 Poland
  • 7.3 South America
    • 7.3.2 Brazil
    • 7.3.3 Argentina
  • 7.4 Asia-Pacific
    • 7.4.2 India
    • 7.4.3 China
    • 7.4.4 Japan
    • 7.4.5 Australia
    • 7.4.6 Vietnam
    • 7.4.7 South Korea
    • 7.4.8 Indonesia
    • 7.4.9 Philippines
  • 7.5 Middle East and Africa
    • 7.5.2 Saudi Arabia
    • 7.5.3 UAE
    • 7.5.4 South Africa

8 Market Mapping, 2023

  • 8.1 By Biomarker Type
  • 8.2 By Technology
  • 8.3 By Cancer Type
  • 8.4 By Application
  • 8.5 By End-user
  • 8.6 By Region

9 Macro Environment and Industry Structure

  • 9.1 Supply Demand Analysis
  • 9.2 Import Export Analysis - Volume and Value
  • 9.3 Supply/Value Chain Analysis
  • 9.4 PESTEL Analysis
    • 9.4.2 Political Factors
    • 9.4.3 Economic System
    • 9.4.4 Social Implications
    • 9.4.5 Technological Advancements
    • 9.4.6 Environmental Impacts
    • 9.4.7 Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 9.5 Porter's Five Forces Analysis
    • 9.5.2 Supplier Power
    • 9.5.3 Buyer Power
    • 9.5.4 Substitution Threat
    • 9.5.5 Threat from New Entrant
    • 9.5.6 Competitive Rivalry

10 Market Dynamics

  • 10.1 Growth Drivers
  • 10.2 Growth Inhibitors (Challenges, Restraints)

11 Regulatory Framework and Innovation

  • 11.1 Clinical Trials
  • 11.2 Patent Landscape
  • 11.3 Regulatory Approvals
  • 11.4 Innovations/Emerging Technologies

12 Key Players Landscape

  • 12.1 Competition Matrix of Top Five Market Leaders
  • 12.2 Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 12.3 Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 12.4 SWOT Analysis (For Five Market Players)
  • 12.5 Patent Analysis (If Applicable)

13 Pricing Analysis

14 Case Studies

15 Key Players Outlook

  • 15.1 Illumina, Inc.
    • 15.1.2 Company Details
    • 15.1.3 Key Management Personnel
    • 15.1.4 Products & Services
    • 15.1.5 Financials (As reported)
    • 15.1.6 Key Market Focus & Geographical Presence
    • 15.1.7 Recent Developments
  • 15.2 QIAGEN NV
  • 15.3 NeoGenomics Laboratories, Inc.
  • 15.4 HTG Molecular Diagnostics, Inc.
  • 15.5 Genomic Health Inc.
  • 15.6 Caris Life Sciences
  • 15.7 Helomics Corporation
  • 15.8 NanoString Technologies, Inc.
  • 15.9 Sysmex Corporation
  • 15.10 Ribomed Biotechnologies, Inc.
  • 15.11 Guardant Health, Inc.
  • 15.12 Foundation Medicine
  • 15.13 Roche Holding AG
  • 15.14 GenScript Biotech Corporation
  • 15.15 Tempus Labs, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

16 Strategic Recommendations

17 About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 4. Global Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 5. Global Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 6. Global Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 7. Global Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 8. Global Cancer Profiling Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 11. North America Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 12. North America Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 13. North America Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 14. North America Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 15. North America Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 16. North America Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 19. United States Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 20. United States Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 21. United States Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 22. United States Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 23. United States Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 24. Canada Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 26. Canada Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 27. Canada Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 28. Canada Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 29. Canada Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 30. Canada Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 31. Mexico Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 33. Mexico Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 34. Mexico Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 35. Mexico Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 36. Mexico Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 37. Mexico Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 38. Europe Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 40. Europe Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 41. Europe Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 42. Europe Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 43. Europe Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 44. Europe Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 45. Europe Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. Germany Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 49. Germany Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 50. Germany Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 51. Germany Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 52. Germany Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 53. France Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 55. France Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 56. France Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 57. France Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 58. France Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 59. France Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 60. Italy Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. Italy Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 63. Italy Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 64. Italy Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 65. Italy Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 66. Italy Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 67. United Kingdom Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. United Kingdom Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 70. United Kingdom Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 71. United Kingdom Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 72. United Kingdom Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 73. United Kingdom Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 74. Russia Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 76. Russia Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 77. Russia Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 78. Russia Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 79. Russia Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 80. Russia Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 81. Netherlands Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 83. Netherlands Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 84. Netherlands Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 85. Netherlands Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 86. Netherlands Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 87. Netherlands Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 88. Spain Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Spain Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 91. Spain Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 92. Spain Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 93. Spain Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 94. Spain Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 95. Turkey Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 97. Turkey Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 98. Turkey Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 99. Turkey Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 100. Turkey Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 101. Turkey Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 102. Poland Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 104. Poland Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 105. Poland Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 106. Poland Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 107. Poland Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 108. Poland Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 109. South America Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. South America Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 112. South America Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 113. South America Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 114. South America Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 115. South America Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 116. South America Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Brazil Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 120. Brazil Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 121. Brazil Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 122. Brazil Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 123. Brazil Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 124. Argentina Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 126. Argentina Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 127. Argentina Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 128. Argentina Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 129. Argentina Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 130. Argentina Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 131. Asia-Pacific Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 133. Asia-Pacific Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 134. Asia-Pacific Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 135. Asia-Pacific Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 136. Asia-Pacific Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 137. Asia- Pacific Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 138. Asia-Pacific Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 139. India Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. India Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 142. India Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 143. India Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 144. India Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 145. India Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 146. China Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 148. China Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 149. China Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 150. China Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 151. China Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 152. China Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 153. Japan Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 155. Japan Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 156. Japan Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 157. Japan Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 158. Japan Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 159. Japan Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 160. Australia Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 162. Australia Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 163. Australia Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 164. Australia Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 165. Australia Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 166. Australia Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 167. Vietnam Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Vietnam Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 170. Vietnam Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 171. Vietnam Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 172. Vietnam Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 173. Vietnam Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 174. South Korea Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 176. South Korea Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 177. South Korea Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 178. South Korea Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 179. South Korea Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 180. South Korea Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 181. Indonesia Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. Indonesia Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 184. Indonesia Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 185. Indonesia Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 186. Indonesia Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 187. Indonesia Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 188. Philippines Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 190. Philippines Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 191. Philippines Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 192. Philippines Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 193. Philippines Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 194. Philippines Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 195. Middle East & Africa Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Middle East & Africa Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 198. Middle East & Africa Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 199. Middle East & Africa Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 200. Middle East & Africa Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 201. Middle East & Africa Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 202. Middle East & Africa Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 205. Saudi Arabia Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 206. Saudi Arabia Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 207. Saudi Arabia Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 208. Saudi Arabia Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 209. Saudi Arabia Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 210. UAE Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 212. UAE Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 213. UAE Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 214. UAE Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 215. UAE Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 216. UAE Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 217. South Africa Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 219. South Africa Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 220. South Africa Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 221. South Africa Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 222. South Africa Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 223. South Africa Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 224. By Biomarker Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023